Climacteric最新文献

{"title":"Mortality trends in US patients with gynecologic cancer and cardiovascular disease.","authors":"Zhong-Qiang Liu, Yu-Jun Xiong, Xiang-Da Meng, Tian Lv, Hao Guo","doi":"10.1080/13697137.2026.2699767","DOIUrl":"10.1080/13697137.2026.2699767","url":null,"abstract":"<p><strong>Objectives: </strong>Female genital organ cancers and cardiovascular disease (CVD) are major contributors to women's morbidity and mortality. Improved cancer survival and increasing cardiometabolic risk may amplify their coexistence, yet population-level mortality patterns remain unclear.</p><p><strong>Methods: </strong>This study analyzed US national death certificate data (1999-2023) for women aged ≥25 years with both gynecologic cancer (ICD‑10 codes C51-C58) and CVD (ICD‑10 codes I00-I99). Age-adjusted mortality rates (AAMRs) were calculated using the 2000 US standard population. Joinpoint regression estimated the annual percentage change (APC) and average annual percentage change (AAPC), stratified by age, race, region and urbanization.</p><p><strong>Results: </strong>A total of 210,966 deaths were identified, representing a 49.0% increase over the study period. The overall AAMR remained stable (7.50-7.62 per 100,000; AAPC 0.01%). Mortality was highest among women aged ≥85 years, with a marked rise after 2018 (APC 5.55%). The West showed sustained increases, whereas the Northeast experienced early declines. Non-Hispanic Black women and non-metropolitan residents consistently had the highest mortality.</p><p><strong>Conclusion: </strong>Although overall mortality remained stable, substantial age, racial, geographic and rural-urban disparities persist. These findings highlight the need for integrated cardio-oncology care and targeted strategies to reduce structural inequities.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"760-768"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The enigma of associations between reproductive health and development of osteoarthritis in midlife: a life-course approach.","authors":"Fiona Kirkham-Wilson, Ikrah Shah, Roshan Rambukwella, Elaine Dennison","doi":"10.1080/13697137.2026.2699763","DOIUrl":"10.1080/13697137.2026.2699763","url":null,"abstract":"<p><p>Osteoarthritis (OA) is the most common form of arthritis. OA becomes more prevalent in women around the age of menopause, and it has been suggested that the decrease in estrogen at menopause may be important in the pathophysiology of OA development. The association between estrogen exposure and OA is complex; a recent meta-analysis suggested that menopause hormone therapy use may be associated with an increased risk of joint replacement, bringing this research area back into focus. This narrative review used a systematic process, adopting a life-course approach to consider relationships between reproductive factors and OA, identifying 15 papers published over a 26-year period. Increased parity, use of the oral contraceptive pill, abortion, breastfeeding and inter-menstrual years were all considered but findings varied widely between studies. We note that progesterone is rarely considered, despite animal work suggesting its importance. These data highlight the need for further research with careful measurements of confounding variables, and consideration of the role for progesterone in OA etiology.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"689-698"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopause care in Brazil: policy recognition and the challenge of implementation.","authors":"Nelio Neves Veiga Junior, Luiz Francisco Cintra Baccaro","doi":"10.1080/13697137.2026.2727328","DOIUrl":"https://doi.org/10.1080/13697137.2026.2727328","url":null,"abstract":"<p><p>Brazil is undergoing rapid demographic aging, with millions of women living decades beyond menopause. Despite having a universal public health system and one of the world's largest primary healthcare (PHC) networks, menopause remains inconsistently integrated into routine care delivery. Over the past four decades, Brazilian public policies have progressively expanded menopause care from a predominantly reproductive and hormone-centered model toward a broader person-centered and equity-oriented approach. The recent preliminary Brazilian Ministry of Health manual on menopausal transition and menopause reinforces the role of PHC, longitudinal care, social determinants of health and health equity in menopause management. However, substantial gaps persist between institutional recognition and implementation. Menopause care remains fragmented, unevenly prioritized and marked by regional and socioeconomic disparities in access to evidence-based therapies and trained professionals. This commentary discusses the evolution of menopause-related public policies in Brazil and argues that the main challenge is no longer recognition of menopause as a public health issue, but the operationalization of equitable and sustainable menopause care within PHC. Brazil has the potential to become a model for menopause care integration in middle-income countries if policy advances are effectively translated into routine care delivery.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-3"},"PeriodicalIF":3.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of hormones in female androgenetic alopecia: focus on menopause.","authors":"Aleksandra Anderson, Piotr Konopelski, Katarzyna Skorzewska, Aleksandra Kuchnicka, Anna Waskiel-Burnat, Lidia Rudnicka","doi":"10.1080/13697137.2026.2699762","DOIUrl":"https://doi.org/10.1080/13697137.2026.2699762","url":null,"abstract":"<p><p>Female androgenetic alopecia (FAGA) is the most common cause of hair loss in women. Even though its prevalence differs between populations, studies show consistent evidence that the incidence increases with age. This can be attributed to hormonal changes during the menopausal transition - a decrease of estrogen levels leading to the state of relative hyperandrogenism. Nonetheless, the pathogenesis of the disease remains unclear, as up-to-date studies have failed to prove the correlation between total and free testosterone concentrations and the prevalence of FAGA. This article provides a literature review on the impact of hormones on the hair cycle and their role in postmenopausal women. In particular, the article focuses on the role of androgens, estrogens, progesterone, stress hormones and hormones released from the adipose tissue in the context of AGA. Furthermore, the article reviews the risk factors of FAGA in postmenopausal women, such as insulin resistance, high body mass index and metabolic syndrome, and elucidates their possible role in the pathogenesis of the disease.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-8"},"PeriodicalIF":3.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global prevalence of vasomotor symptoms in the menopause transition: systematic review and meta-analysis.","authors":"Shahara Aziz Ellahi, Aimee Spector, Vikram Talaulikar, Alexandra Faulkner, Roopal Desai","doi":"10.1080/13697137.2026.2722609","DOIUrl":"https://doi.org/10.1080/13697137.2026.2722609","url":null,"abstract":"<p><strong>Objective: </strong>Vasomotor symptoms (VMS) are common symptoms experienced during the menopausal transition. Previous reviews have highlighted regional heterogeneity but have not quantitatively pooled prevalence estimates. This study estimated pooled VMS prevalence across five global regions using a systematic review and meta-analysis.</p><p><strong>Method: </strong>MEDLINE, PsycINFO, CINAHL and Web of Science were searched from database inception to January 2025. Population-based studies reporting VMS prevalence among perimenopausal or postmenopausal women aged 40-65 years published from 2014 onwards (minimum sample size of 200) were included. Data were extracted using a standardized template. Random-effects meta-analyses determined pooled prevalence estimates, with heterogeneity assessed using <i>I</i>².</p><p><strong>Results: </strong>Forty-one studies (<i>n</i> = 28,955) were included. Pooled prevalence estimates ranged from 54.29% in Africa to 74.23% in the Americas and Europe. Heterogeneity was high across analyses (<i>I</i>² > 97%). Prevalence was higher in postmenopausal than perimenopausal women in all regions except South Asia and nearby regions. Pooled prevalence estimates differed between geographical regions, although substantial heterogeneity suggests these differences should be interpreted cautiously. The heterogeneity observed indicates that biological factors alone do not explain variation in VMS, highlighting cultural and methodological influence.</p><p><strong>Conclusion: </strong>These findings support culturally sensitive and context-specific approaches to menopause care and management.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-14"},"PeriodicalIF":3.9,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of fezolinetant on sleep, health-related quality of life and work productivity.","authors":"Antonio Cano, Genevieve Neal Perry, Karla Martins, Antonia Morga, Arianne Schild, Rossella E Nappi, Marla Shapiro, Nanette Santoro","doi":"10.1080/13697137.2026.2715238","DOIUrl":"https://doi.org/10.1080/13697137.2026.2715238","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate fezolinetant's impact on sleep disturbance and impairment in women with moderate to severe vasomotor symptoms (VMS) due to menopause and explore relationships between VMS improvement and work productivity.</p><p><strong>Method: </strong>This post-hoc analysis of SKYLIGHT 1 and 2 pooled data assessed sleep disturbance and impairment via the Patient-Reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD-SF-8b) and PROMIS SD-SF-8a questionnaires. Correlations were evaluated between improvements in VMS (frequency, severity, frequency at night) and sleep disturbance and Work Productivity and Activity Impairment questionnaire specific to Vasomotor Symptoms (WPAI-VMS) score; and sleep disturbance and work productivity.</p><p><strong>Results: </strong>Fezolinetant 30 mg and 45 mg improved sleep disturbance and impairment versus placebo at 12 weeks, regardless of baseline sleep status. At weeks 12 and 52, both doses showed correlations between VMS frequency/severity and WPAI-VMS productivity scores, and between sleep disturbance and work productivity.</p><p><strong>Conclusion: </strong>Fezolinetant reduced moderate to severe VMS due to menopause and improved patient-reported sleep outcomes, with benefits maintained over 1 year. Improvements in VMS and sleep were associated with better work productivity.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-8"},"PeriodicalIF":3.9,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between triglyceride-glucose-related indices and reproductive lifespan: a cross-sectional study from the NHANES (2007-2020).","authors":"Lei Ding, Ting Jiang, Xuexiu Jia","doi":"10.1080/13697137.2026.2722605","DOIUrl":"https://doi.org/10.1080/13697137.2026.2722605","url":null,"abstract":"<p><strong>Objective: </strong>The female reproductive lifespan, characterized by the period spanning from menarche to menopause, may be modulated by metabolic health factors. This cross-sectional analysis utilized nationally representative survey data from the National Health and Nutrition Examination Survey (NHANES) to explore the linkages between three triglyceride-glucose (TyG)-related adiposity metrics and parameters of the female reproductive lifespan.</p><p><strong>Method: </strong>The study analyzed data from female participants in multiple NHANES cycles (2007-2020). The female reproductive lifespan was computed using self-reported ages at menarche and menopause. Associations of continuous TyG indices (and their tertiles) with female reproductive lifespan, age at menarche, and age at menopause were evaluated using weighted multivariable linear regression. Non-linear patterns were examined using restricted cubic splines, and subgroup analyses were tested for potential effect modifications.</p><p><strong>Results: </strong>Following full adjustment (Model 3), all TyG indices displayed significant positive correlations with both female reproductive lifespan (e.g. TyG-BMI: <i>β</i> = 1.23, 95% confidence interval [CI] 0.71 to 1.75, <i>p</i> < 0.001) and age at menopause (e.g. TyG-WC: <i>β</i> = 1.07, 95% CI 0.59 to 1.54, <i>p</i> < 0.001). Conversely, significant negative correlations were noted with age at menarche (e.g. TyG-WHtR: <i>β</i> = -0.24, 95% CI -0.41 to -0.07, <i>p</i> = 0.006). Participants in the highest tertile (T3) of each TyG index consistently showed longer female reproductive lifespans and later menopause compared to the lowest tertile (T1), alongside an earlier onset of menarche. Significant positive trends across tertiles were evident for female reproductive lifespan and age at menopause for all indices, while significant inverse trends emerged for age at menarche.</p><p><strong>Conclusion: </strong>Elevated levels of TyG-BMI, TyG-WC and TyG-WHtR - composite indices integrating insulin resistance and adiposity - demonstrate consistent associations with a prolonged female reproductive lifespan.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perimenopausal symptom burden: implications for health, work and earlier clinical management.","authors":"Doris Rodríguez-Vidal, Juan E Blümel, Peter Chedraui, María S Vallejo, Lucia Costa-Paiva, Hugo Gutiérrez-Crespo, Maribel Dextre, Karen Díaz, Alejandra Elizalde-Cremonte, Santiago Elizalde-Cremonte, Carlos Escalante-Gómez, María T Espinoza, Ircania García, Gustavo Gómez-Tabares, Juan Matzumura-Kasano, Paolo Meza, Álvaro Monterrosa-Castro, Mónica Ñañez, Marcela López, Eliana Ojeda, Claudia Rey, Ana Lucia Ribeiro Valadares, Marcio A H Rodrigues, Javier Saavedra, Carlos Salinas, Lida Sosa, Konstantinos Tserotas, Margot Acuña-San Martín, Sócrates Aedo, Marcela S Aguirre, Eugenio Arteaga, Félix Ayala, Ascanio Bencosme, Andrés Calle","doi":"10.1080/13697137.2026.2715247","DOIUrl":"10.1080/13697137.2026.2715247","url":null,"abstract":"<p><strong>Objective: </strong>Perimenopausal women often experience symptoms impairing quality of life, yet they receive limited clinical attention. This study aimed to assess symptom burden, health-related quality of life (HRQoL) and work-related outcomes across reproductive aging stages.</p><p><strong>Method: </strong>Secondary analysis included 1478 women aged 40-54 years from 12 Latin American countries, classified by age and menstrual status into four groups: age 40-44 years with regular cycles (reference), age 45-49 years with regular cycles, age 45-49 years with irregular cycles (perimenopause) and age 50-54 years with absent menses (early postmenopause). Symptoms, HRQoL, work-related outcomes and job satisfaction were assessed using validated instruments Multivariable logistic regression analyses were performed.</p><p><strong>Results: </strong>Symptom severity increased progressively across stages, with severe symptoms rising from 18.3% (reference group) to 50.6% in postmenopausal women (<i>p</i> < 0.001). Compared with the reference group, women with irregular cycles and those with absent menses had higher odds of severe symptoms (odds ratio [OR] 2.97 and 3.71), lower HRQoL (OR 1.62 and 1.97) and lower job satisfaction (OR 2.01 and 3.07), respectively. Menopausal stage was not independently associated with work-related quality of life.</p><p><strong>Conclusion: </strong>Symptom burden and its impact on health and job satisfaction emerge before menopause and may inform earlier, stage-specific clinical guidance.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-9"},"PeriodicalIF":3.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is in the bottle? An analysis of the ingredients in menopause supplements.","authors":"Poppy Sullivan, Anne-Marie Boylan, Joyce Catherine Harper","doi":"10.1080/13697137.2026.2719016","DOIUrl":"https://doi.org/10.1080/13697137.2026.2719016","url":null,"abstract":"<p><strong>Objective: </strong>Menopause supplements are a global market projected to reach $25 billion by 2030, despite a lack of evidence on their efficacy. This study analyzed the ingredients, doses and costs of menopause supplements in the UK.</p><p><strong>Method: </strong>A systematic search of nine UK retailers and Google Shopping was conducted using the terms 'menopause' and 'menopause supplements'. Products with the term 'menopause' in their name or description were included; duplicates, bundles and discontinued items were excluded. Ingredients were categorized as vitamins and minerals, botanicals, and other active and non-active ingredients. Doses and costs were recorded.</p><p><strong>Results: </strong>We identified 201 menopause supplements. Herbs (80.1%), vitamins (76.6%) and phytoestrogens (74.1%) were the most common ingredients. Vitamin B6 appeared in 69.2% of products, while zinc and magnesium were found in 48.8% and 47.3%, respectively. Red clover (38.8%) and sage (42.8%) were the most common phytoestrogen and herb. Costs ranged from £1.50 to £95 per month.</p><p><strong>Conclusion: </strong>Menopause supplements contain highly variable ingredients and are often expensive. They are being sold to women as a way to reduce menopause symptoms despite the limited empirical evidence currently available. Healthcare professionals should be aware of the wide variability in supplement formulations and discuss evidence-based treatment options with women considering these products.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-15"},"PeriodicalIF":3.9,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148929136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perimenopause and metabolic vulnerability: hormones, body composition and lifestyle changes.","authors":"Vanessa Alves Lobato, Tatiana Palotta Minari, Luciana Pellegrini Pisani","doi":"10.1080/13697137.2026.2713394","DOIUrl":"https://doi.org/10.1080/13697137.2026.2713394","url":null,"abstract":"<p><p>Perimenopause is a transitional phase characterized by substantial hormonal fluctuations, particularly declining estradiol levels, accompanied by age-related metabolic changes. Increasing evidence suggests that this period constitutes a critical window of metabolic vulnerability, marked by adverse alterations in body composition, energy metabolism and cardiometabolic health. Notably, these changes may develop even without significant increases in body weight, potentially delaying their recognition in clinical settings. A narrative review was conducted using the PubMed/MEDLINE, Scopus, Web of Science and SciELO databases. Studies involving perimenopausal women, plus relevant animal models, were included. Search terms covered estrogen deficiency, body composition, metabolism, insulin resistance, inflammation, physical activity and nutrition. Fifty-six studies published between 2000 and 2026 were analyzed. Evidence shows that perimenopause is characterized by increased visceral fat, loss of lean mass, reduced fat oxidation and impaired metabolic flexibility, even without major weight changes. Declining estrogen drives adipose redistribution, muscle dysfunction, hepatic insulin resistance and chronic low-grade inflammation. These changes heighten risk for metabolic syndrome, type 2 diabetes and cardiovascular events. Lifestyle interventions, particularly resistance training and Mediterranean diet adherence, demonstrate strong potential to preserve muscle, improve insulin sensitivity and reduce inflammation. In conclusion, perimenopause should be recognized as a pivotal stage for early detection and prevention of metabolic dysfunction. Lifestyle-based interventions during this phase may reduce long-term cardiometabolic risk and improve women's health.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-16"},"PeriodicalIF":3.9,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}